Literature DB >> 1913549

Primary extracranial neuroblastoma with central nervous system metastases characterization by clinicopathologic findings and neuroimaging.

S J Kellie1, F A Hayes, L Bowman, E H Kovnar, J Langston, J J Jenkins, W J Pao, R Ducos, A A Green.   

Abstract

The authors report the clinicopathologic and neuroimaging findings in ten children with primary abdominal or thoracic neuroblastoma who relapsed in the central nervous system (CNS) without evidence of concurrent intracranial extension from adjacent bone, dura, or dural sinus metastases. At diagnosis, the patients ranged in age from 0.3 to 4.5 years (median, 2 years). Their times to CNS relapse ranged from 2 to 34 months from diagnosis. In seven patients the relapse occurred from 1 to 14 months after elective discontinuation of therapy. In four patients, the CNS relapse was the primary (isolated) adverse event. Four patients could not be treated at the time of relapse, and they died within 7 days of progressive CNS disease. In the remaining group, craniospinal irradiation with or without administration of a platinum compound and an epipodophyllotoxin caused complete CNS remissions lasting 4, 5, 16, and 62+ months. Neuroimaging and autopsy findings indicated that cerebrospinal fluid is the major pathway for neuraxis dissemination by neuroblastoma cells. There was no evidence of dural penetration in any patient. The possibility of relapse in the neuraxis should be considered for any patient with neuroblastoma who had neurologic deterioration. A combination of craniospinal radiation and administration of a platinum compound and an epipodophyllotoxin will induce complete responses in some patients with neuraxis involvement by neuroblastoma, but the risk of subsequent failure outside the CNS remains high.

Entities:  

Mesh:

Year:  1991        PMID: 1913549     DOI: 10.1002/1097-0142(19911101)68:9<1999::aid-cncr2820680926>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid.

Authors:  Ping He; Kim Kramer; Peter Smith-Jones; Pat Zanzonico; John Humm; Steven M Larson; Nai-Kong V Cheung
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-10-09       Impact factor: 9.236

2.  Isolated central nervous system relapses in patients with high-risk neuroblastoma -clinical presentation and prognosis: experience of the Polish Paediatric Solid Tumours Study Group.

Authors:  Aleksandra Wieczorek; Joanna Stefanowicz; Marcin Hennig; Elzbieta Adamkiewicz-Drozynska; Marzena Stypinska; Bozenna Dembowska-Baginska; Zuzanna Gamrot; Mariola Woszczyk; Julia Geisler; Tomasz Szczepanski; Szymon Skoczen; Marek Ussowicz; Monika Pogorzala; Szymon Janczar; Walentyna Balwierz
Journal:  BMC Cancer       Date:  2022-06-25       Impact factor: 4.638

3.  Neurological complications of neuroblastic tumors: experience of a single center.

Authors:  G Burca Aydin; M Tezer Kutluk; Munevver Buyukpamukcu; Canan Akyuz; Bilgehan Yalcin; Ali Varan
Journal:  Childs Nerv Syst       Date:  2009-08-28       Impact factor: 1.475

4.  PET-CT in detection of meningeal metastasis in neuroblastoma.

Authors:  Madhavi Chawla; Ramamohan Reddy; Rajender Kumar; Chandan J Das; Sandeep Agarwala; Amar M Tiwari; Arun Malhotra; Rakesh Kumar
Journal:  Pediatr Surg Int       Date:  2009-01-08       Impact factor: 1.827

5.  Hemorrhagic intracranial parenchymal metastases from primary retroperitoneal neuroblastoma.

Authors:  M R Aronson; W R Smoker; G M Oetting
Journal:  Pediatr Radiol       Date:  1995

6.  Intracranial metastatic neuroblastoma treated with gamma knife stereotactic radiosurgery: report of two novel cases.

Authors:  Nathan C Rowland; Jennifer Andrews; Daxa Patel; David V Laborde; Adam Nowlan; Bradley George; Claire Mazewski; Andrew Reisner; Howard M Katzenstein
Journal:  Case Rep Neurol Med       Date:  2012-01-19

7.  The choroid plexus may be an underestimated site of tumor invasion to the brain: an in vitro study using neuroblastoma cell lines.

Authors:  Martin März; Michael Karremann; Elodie Vandenhaute; Carolin Stump-Guthier; María Lasierra Losada; Tobias Tenenbaum; Henriette Rudolph; Hiroshi Ishikawa; Christian Schwerk; Horst Schroten; Matthias Dürken
Journal:  Cancer Cell Int       Date:  2015-10-24       Impact factor: 5.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.